Drug Profile
Dimethyl fumarate - Biogen
Alternative Names: BG-00012; BG-12; BG-12 oral fumarate; Delayed-release dimethyl fumarate; Delayed-release DMF; FAG-201; Gastro-resistant dimethyl fumarate; Gastro-resistant DMF; Panaclar; TecfideraLatest Information Update: 08 Dec 2022
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer Biogen; Biogen Idec
- Class Anti-inflammatories; Antihypertensives; Antipsoriatics; Antirheumatics; Cardiovascular therapies; Cytoprotectives; Esters; Fumarates; Small molecules
- Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis
- Phase II Psoriasis
- No development reported Pulmonary arterial hypertension; Rheumatoid arthritis
Most Recent Events
- 06 Dec 2022 The Enlarged Board of Appeal (the EBA) of the European Patent Office dismisses decision of the Technical Board of Appeal of the EPO Opposition Division to revoke the EP2801355 patent
- 21 Jul 2022 Biogen terminates a phase III in Multiple sclerosis (In children's, In adolescents, Combination therapy) in Colombia, Jordan, South Korea, Malaysia, Mexico, Saudi Arabia, Taiwan, Thailand, Tunisia, Turkey, Estonia, Hungary and USA (SC, Injection) due to long-term difficulties in fulfilling enrolment commitments(NCT03870763)
- 21 Jun 2022 Biogen has patent protection related to dimethyl fumarate for treatment of multiple sclerosis in European Union